Role of asymmetric dimethylarginine in cardiorenal syndrome

Related Experiment Video

Updated: May 9, 2026

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

Seiji Ueda, Sho-Ichi Yamagishi, Miyuki Yokoro

  • 1Division of Nephrology, Department of Medicine, Kurume University School of Medicine, Kurume 830-0011, Japan. ueda@med.kurume-u.ac.jp.

Current Pharmaceutical Design
|July 13, 2013
PubMed

Insights

Asymmetric dimethylarginine (ADMA) contributes to endothelial dysfunction, potentially explaining the link between cardiovascular disease and chronic kidney disease in cardiorenal syndrome. Elevated ADMA levels predict worse outcomes in these patients.

Area of Science:

  • Nephrology
  • Cardiology
  • Vascular Biology

Background:

  • Cardiorenal syndrome (CRS) involves a detrimental interplay between cardiovascular disease (CVD) and chronic kidney disease (CKD).
  • The exact mechanisms driving CRS progression remain unclear, hindering effective treatment strategies.
  • Endothelial dysfunction (ED) is implicated in both atherosclerosis and renal injury, suggesting a potential link in CRS.

Purpose of the Study:

  • To explore the role of asymmetric dimethylarginine (ADMA) in the development of endothelial dysfunction.
  • To investigate the contribution of ADMA-mediated ED to the pathogenesis of cardiorenal syndrome in CKD patients.

Main Methods:

  • Literature review focusing on studies investigating ADMA, endothelial dysfunction, and cardiorenal syndrome.
  • Analysis of existing clinical data linking ADMA levels to cardiovascular events and CKD progression.

Main Results:

  • Asymmetric dimethylarginine (ADMA) is an endogenous nitric oxide synthase inhibitor.
  • Plasma ADMA levels are elevated in patients with chronic kidney disease.
  • Increased ADMA is an independent predictor of cardiovascular events and CKD progression.

Conclusions:

  • Accumulated ADMA-mediated endothelial dysfunction is a significant factor in the development of cardiorenal syndrome.
  • Targeting ADMA pathways may offer a therapeutic strategy for managing CRS in CKD patients.

More Related Videos

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...